261 related articles for article (PubMed ID: 15112170)
1. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial.
Fung JW; Szeto CC; Chan WW; Kum LC; Chan AK; Wong JT; Wu EB; Yip GW; Chan JY; Yu CM; Woo KS; Sanderson JE
Am J Kidney Dis; 2004 May; 43(5):801-8. PubMed ID: 15112170
[TBL] [Abstract][Full Text] [Related]
2. [Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC)].
Vallero A; Cesano G; Pozzato M; Garbo R; Minelli M; Quarello F; Formica M
G Ital Nefrol; 2002; 19(5):529-33. PubMed ID: 12439841
[TBL] [Abstract][Full Text] [Related]
3. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial.
Kay J; Chow WH; Chan TM; Lo SK; Kwok OH; Yip A; Fan K; Lee CH; Lam WF
JAMA; 2003 Feb; 289(5):553-8. PubMed ID: 12578487
[TBL] [Abstract][Full Text] [Related]
4. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
[TBL] [Abstract][Full Text] [Related]
5. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies.
Briguori C; Airoldi F; D'Andrea D; Bonizzoni E; Morici N; Focaccio A; Michev I; Montorfano M; Carlino M; Cosgrave J; Ricciardelli B; Colombo A
Circulation; 2007 Mar; 115(10):1211-7. PubMed ID: 17309916
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography.
Durham JD; Caputo C; Dokko J; Zaharakis T; Pahlavan M; Keltz J; Dutka P; Marzo K; Maesaka JK; Fishbane S
Kidney Int; 2002 Dec; 62(6):2202-7. PubMed ID: 12427146
[TBL] [Abstract][Full Text] [Related]
7. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
[TBL] [Abstract][Full Text] [Related]
8. Prevention of acute renal failure post-contrast imaging in cardiology: a randomized study.
Alessandri N; Lanzi L; Garante CM; Tersigni F; Sergiacomi R; Petrassi M; Di Matteo A; Tufano F
Eur Rev Med Pharmacol Sci; 2013 Feb; 17 Suppl 1():13-21. PubMed ID: 23436661
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial.
Brueck M; Cengiz H; Hoeltgen R; Wieczorek M; Boedeker RH; Scheibelhut C; Boening A
J Invasive Cardiol; 2013 Jun; 25(6):276-83. PubMed ID: 23735352
[TBL] [Abstract][Full Text] [Related]
10. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine.
Rashid ST; Salman M; Myint F; Baker DM; Agarwal S; Sweny P; Hamilton G
J Vasc Surg; 2004 Dec; 40(6):1136-41. PubMed ID: 15622367
[TBL] [Abstract][Full Text] [Related]
11. Prevention of contrast agent-induced renal impairment in patients with chronic renal insufficiency and heart disease by high-dose intravenous N-acetylcysteine: a pilot-ministudy.
Sochman J; Krizova B
Kardiol Pol; 2006 Jun; 64(6):559-64; discussion 565-6. PubMed ID: 16810570
[TBL] [Abstract][Full Text] [Related]
12. Is treatment with N-acetylcysteine to prevent contrast-induced nephropathy when using bicarbonate hydration out of date?
Heng AE; Cellarier E; Aublet-Cuvelier B; Decalf V; Motreff P; Marcaggi X; Deteix P; Souweine B
Clin Nephrol; 2008 Dec; 70(6):475-84. PubMed ID: 19049703
[TBL] [Abstract][Full Text] [Related]
13. Reno-protective effect of N-acetyl cysteine in patients with impaired renal function undergoing coronary angiography and interventions.
Ramesh N; Pillai RK; Abraham T; Padmaja NP; Hameed S; Vijayaraghavan G
J Assoc Physicians India; 2006 Jun; 54():449-52. PubMed ID: 16909692
[TBL] [Abstract][Full Text] [Related]
14. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results.
Kimmel M; Butscheid M; Brenner S; Kuhlmann U; Klotz U; Alscher DM
Nephrol Dial Transplant; 2008 Apr; 23(4):1241-5. PubMed ID: 18174269
[TBL] [Abstract][Full Text] [Related]
15. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of acetylcysteine in prevention of contrast nephropathy.
Azmus AD; Gottschall C; Manica A; Manica J; Duro K; Frey M; Bulcão L; Lima C
J Invasive Cardiol; 2005 Feb; 17(2):80-4. PubMed ID: 15687530
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect.
Webb JG; Pate GE; Humphries KH; Buller CE; Shalansky S; Al Shamari A; Sutander A; Williams T; Fox RS; Levin A
Am Heart J; 2004 Sep; 148(3):422-9. PubMed ID: 15389228
[TBL] [Abstract][Full Text] [Related]
18. N-acethyl-cysteine reduces the occurrence of contrast-induced acute kidney injury in patients with renal dysfunction: a single-center randomized controlled trial.
Heguilén RM; Liste AA; Payaslian M; Ortemberg MG; Albarracín LM; Bernasconi AR
Clin Exp Nephrol; 2013 Jun; 17(3):396-404. PubMed ID: 23138396
[TBL] [Abstract][Full Text] [Related]
19. Does intravenous or oral high-dose N-acetylcysteine in addition to saline prevent contrast-induced nephropathy assessed by cystatin C?
Erturk M; Uslu N; Gorgulu S; Akbay E; Kurtulus G; Akturk IF; Akgul O; Surgit O; Uzun F; Gul M; Isiksacan N; Yildirim A
Coron Artery Dis; 2014 Mar; 25(2):111-7. PubMed ID: 24365793
[TBL] [Abstract][Full Text] [Related]
20. Preventive effects of anisodamine against contrast-induced nephropathy in type 2 diabetics with renal insufficiency undergoing coronary angiography or angioplasty.
Geng W; Fu XH; Gu XS; Wang YB; Wang XC; Li W; Jiang YF; Hao GZ; Fan WZ; Xue L
Chin Med J (Engl); 2012 Oct; 125(19):3368-72. PubMed ID: 23044290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
